Last reviewed · How we verify

NCT04735419: iGBS3

Development of a Serocorrelate of Protection Against Invasive Group B Streptococcus Disease

Status unknown Last updated 22 November 2023
What this trial tests

trial testing No intervention in Streptococcus Agalactiae Infection in 400 participants. Status unknown.

Timeline
1 December 2021
Primary endpoint
30 March 2024
30 March 2024

Quick facts

Lead sponsorSt George's, University of London
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment400
Start date1 December 2021
Primary completion30 March 2024
Estimated completion30 March 2024
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

St George's, University of London

Who can join

0 Days and older, any sex, with Streptococcus Agalactiae Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A multicentre study to provide evidence that the relationship between an immune marker value (anti-GBS IgG concentration) and the probability of invasive GBS (iGBS) disease in infants less than 90 days of age is sufficiently strong that a vaccine able to induce an immune response will lead to a meaningful decrease in the probability of iGBS disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Immediate birth for women between 34 and 37 weeks of gestation with prolonged preterm prelabour rupture of membranes and detection of vaginal or urine group B streptococcus: an economic evaluation.
    Dietz J, Plumb J, Banfield P, Soe A, et al · · 2022 · cited 4× · PMID 35137528 · DOI 10.1111/1471-0528.17119

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Streptococcus Agalactiae Infection

Currently open trials in the same condition.

Other St George's, University of London trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04735419.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing